{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:23Z","timestamp":1790236643695,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Amyloidosis is a systemic disease characterized by extracellular deposits of insoluble amyloid in various tissues and organs. Cardiac amyloidosis is a frequent feature of the disease, causing a progressive, restrictive type of cardiomyopathy, and is associated with adverse clinical outcomes and increased mortality. The typical clinical presentation in patients with cardiac amyloidosis is heart failure (HF) with preserved ejection fraction. Most patients present with typical symptoms and signs of HF, such as exertional dyspnea, pretibial edema, pleural effusions and angina pectoris due to microcirculatory dysfunction. However, patients may also frequently encounter various arrhythmias, such as atrioventricular nodal block, atrial fibrillation and ventricular tachyarrhythmias. The management of arrhythmias in cardiac amyloidosis patients with drugs and devices is often a clinical challenge. Moreover, predictors of life-threatening arrhythmic events are not well defined. This review intends to give a deepened insight into the arrhythmic features of cardiac amyloidosis by discussing the pathogenesis of these arrhythmias, addressing the challenges in risk stratification and strategies for management in these patients.<\/jats:p>","DOI":"10.3390\/jcm12072581","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T01:31:30Z","timestamp":1680139890000},"page":"2581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management"],"prefix":"10.3390","volume":"12","author":[{"given":"Natallia","family":"Laptseva","sequence":"first","affiliation":[{"name":"Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"},{"name":"Amyloidosis Network Zurich, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-6597","authenticated-orcid":false,"given":"Valentina A.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[{"name":"Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Schwotzer","sequence":"additional","affiliation":[{"name":"Amyloidosis Network Zurich, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Clinic for Medical Oncology and Hematology, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0596","authenticated-orcid":false,"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[{"name":"Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"},{"name":"Amyloidosis Network Zurich, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-0630","authenticated-orcid":false,"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[{"name":"Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"},{"name":"Amyloidosis Network Zurich, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-0158","authenticated-orcid":false,"given":"Firat","family":"Duru","sequence":"additional","affiliation":[{"name":"Division of Arrhythmia and Electrophysiology, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland"},{"name":"Center for Integrative Human Physiology, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Hawkins","year":"2018","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.hfc.2022.02.005","article-title":"Cardiac Amyloidosis","volume":"18","author":"Gertz","year":"2022","journal-title":"Heart Fail. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stelmach-Go\u0142dy\u015b, A., Zaborek-\u0141yczba, M., \u0141yczba, J., Garus, B., Pasiarski, M., Mertowska, P., Ma\u0142kowska, P., Hrynkiewicz, R., Nied\u017awiedzka-Rystwej, P., and Grywalska, E. (2022). Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040911"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis","volume":"126","author":"Quarta","year":"2012","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"w20364","DOI":"10.4414\/smw.2020.20364","article-title":"Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis","volume":"150","author":"Schwotzer","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"w30053","DOI":"10.4414\/SMW.2021.w30053","article-title":"Management of transthyretin amyloidosis","volume":"151","author":"Condoluci","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Li\u017cewska-Springer, A., S\u0142awi\u0144ski, G., and Lewicka, E. (2021). Arrhythmic Sudden Cardiac Death and the Role of Implantable Cardioverter-Defibrillator in Patients with Cardiac Amyloidosis\u2014A Narrative Literature Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091858"},{"key":"ref_9","first-page":"615","article-title":"Isolated cardiac involvement in primary amyloidosis: Presenting as sick sinus syndrome and heart failure","volume":"40","author":"Pattanshetty","year":"2013","journal-title":"Tex. Heart Inst. J."},{"key":"ref_10","first-page":"e13922","article-title":"A Case Report of Sick Sinus Syndrome as an Initial Presentation of Primary Amyloidosis","volume":"13","author":"Abdelazeem","year":"2021","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lindow, T., and Lindqvist, P. (2021). The Prevalence of Advanced Interatrial Block and Its Relationship to Left Atrial Function in Patients with Transthyretin Cardiac Amyloidosis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132764"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e006619","DOI":"10.1161\/CIRCHEARTFAILURE.119.006619","article-title":"Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis","volume":"13","author":"Cappelli","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac Implantable Electronic Devices: A Window into the Evolution of Conduction Disease in Cardiac Amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac Thrombosis and Embolism in Patients with Cardiac Amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/joa3.12376","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath","year":"2020","journal-title":"J. Arrhythmia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tsch\u00f6pe, C., and Elsanhoury, A. (2022). Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082148"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamilin cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.37.9.711","article-title":"Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine","volume":"37","author":"Griffiths","year":"1982","journal-title":"Thorax"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101366","DOI":"10.1016\/j.cpcardiol.2022.101366","article-title":"A Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment","volume":"47","author":"Bath","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/joa3.12775","article-title":"Digoxin in amyloidosis: Is it associated with a greater incidence of arrhythmogenic potential?","volume":"38","author":"Ibrahim","year":"2022","journal-title":"J. Arrhythmia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin Use in Cardiac Amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: Contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: A systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2021.07.028","article-title":"Management Strategies for Atrial Fibrillation and Flutter in Patients with Transthyretin Cardiac Amyloidosis","volume":"157","author":"Dale","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic Abnormalities in AL (Primary) Amyloidosis With Cardiac Involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","first-page":"1474","article-title":"Sudden death in lambda light chain AL cardiac amyloidosis: A review of literature and update for clinicians and pathologists","volume":"13","author":"Mazzanti","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Frustaci, A., Verardo, R., Russo, M.A., Caldarulo, M., Alfarano, M., Galea, N., Miraldi, F., and Chimenti, C. (2023). Infiltration of Conduction Tissue Is a Major Cause of Electrical Instability in Cardiac Amyloidosis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051798"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1532-429X-12-30","article-title":"Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy","volume":"12","author":"Fluechter","year":"2010","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e012097","DOI":"10.1161\/JAHA.119.012097","article-title":"Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities","volume":"8","author":"Orini","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jce.14541","article-title":"Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis","volume":"31","author":"Halawa","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jmri.22602","article-title":"Dynamic late gadolinium enhancement simply quantified using myocardium to lumen signal ratio: Normal range of ratio and diffuse abnormal enhancement of cardiac amyloidosis","volume":"34","author":"Kono","year":"2011","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00380-015-0658-0","article-title":"Late gadolinium enhancement in cardiac amyloidosis: Attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia","volume":"31","author":"Hashimura","year":"2016","journal-title":"Heart Vessel."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:06:09Z","timestamp":1760123169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072581"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072581","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}